Download PDF
Horm Metab Res 2021; 53(11): 738-745
DOI: 10.1055/a-1666-8979
Endocrine Care

Effects of Metformin and Exercise in Polycystic Ovary Syndrome: Systematic Review and Meta-Analysis

Yu Song 
1   Department of Obstetrics and Gynecology, The Third Hospital of Wuhan, HuBei, China
,
Huimin Wang
1   Department of Obstetrics and Gynecology, The Third Hospital of Wuhan, HuBei, China
,
Zhengyan Zhu
1   Department of Obstetrics and Gynecology, The Third Hospital of Wuhan, HuBei, China
,
Hongli Huang
1   Department of Obstetrics and Gynecology, The Third Hospital of Wuhan, HuBei, China
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

Polycystic ovary syndrome (PCOS) is a common endocrine disorder in women of reproductive age. Metformin is introduced for treatment of women with PCOS, and the beneficial effects of exercise in women with PCOS are found for a range of outcomes. Our aim is to compare the effects of metformin plus exercise with exercise intervention in PCOS on clinical, anthropometric, metabolic, and psychological parameters. MEDLINE, EMBASE, Web of Science and China National Knowledge Infrastructure were searched for studies. Nine studies were considered eligible for inclusion. The meta-analysis reveals that metformin offers additive benefits to exercise, leading to modest improvements in menstrual cycles, hyperandrogenism, and abdominal fat.

Key words

metformin - exercise - polycystic ovary syndrome (PCOS)


Publication History

Received: 11 November 2020

Accepted after revision: 01 October 2021

Article published online:
05 November 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 March WA, Moore VM, Willson KJ. et al The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 2010; 25: 544-551
    CrossrefPubMedGoogle Scholar
  • 2 Ma YM, Li R, Qiao J. et al Characteristics of abnormal menstrual cycle and polycystic ovary syndrome in community and hospital populations. Chin Med J 2010; 123: 2185-2189
    PubMedGoogle Scholar
  • 3 Fauser B, Chang J, Azziz R. et al Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19: 41-47
    CrossrefPubMedGoogle Scholar
  • 4 Apridonidze T, Essah PA, Iuorno MJ. et al Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90: 1929-1935
    CrossrefPubMedGoogle Scholar
  • 5 Azziz R, Carmina E, Chen Z. et al Polycystic ovary syndrome. Nat Rev Dis Primers 2016; 2: 16057
    CrossrefPubMedGoogle Scholar
  • 6 Himelein MJ, Thatcher SS. Depression and body image among women with polycystic ovary syndrome. J Health Psychol 2006; 11: 613-625
    CrossrefPubMedGoogle Scholar
  • 7 Moran LJ, Deeks AA, Gibson-Helm ME. et al Psychological parameters in the reproductive phenotypes of polycystic ovary syndrome. Hum Reprod 2012; 27: 2082-2088
    CrossrefPubMedGoogle Scholar
  • 8 Benham JL, Yamamoto JM, Friedenreich CM. et al Role of exercise training in polycystic ovary syndrome: a systematic review and meta-analysis. Clin Obes 2018; 8: 275-284
    CrossrefPubMedGoogle Scholar
  • 9 Kite C, Lahart IM, Afzal I. et al Exercise, or exercise and diet for the management of polycystic ovary syndrome: a systematic review and meta-analysis. Syst Rev 2019; 8: 51
    CrossrefPubMedGoogle Scholar
  • 10 Moran LJ, Hutchison SK, Norman RJ. et al Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev 2011; CD007506 DOI: 10.1002/14651858.CD007506.pub2.
    CrossrefPubMedGoogle Scholar
  • 11 Harrison CL, Stepto NK, Hutchison SK. et al The impact of intensified exercise training on insulin resistance and fitness in overweight and obese women with and without polycystic ovary syndrome. Clin Endocrinol 2012; 76: 351-357
    CrossrefPubMedGoogle Scholar
  • 12 Thomson RL, Buckley JD, Brinkworth GD. Exercise for the treatment and management of overweight women with polycystic ovary syndrome: a review of the literature. Obes Rev 2011; 12: e202-e210
    CrossrefPubMedGoogle Scholar
  • 13 Moran L, Norman RJ. Understanding and managing disturbances in insulin metabolism and body weight in women with polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 2004; 18: 719-736
    CrossrefPubMedGoogle Scholar
  • 14 Kay SJ, Fiatarone Singh MA. The influence of physical activity on abdominal fat: a systematic review of the literature. Obes Rev 2006; 7: 183-200
    CrossrefPubMedGoogle Scholar
  • 15 Ross R, Freeman JA, Janssen I. Exercise alone is an effective strategy for reducing obesity and related comorbidities. Exerc Sport Sci Rev 2000; 28: 165-170
    PubMedGoogle Scholar
  • 16 Moro C, Pasarica M, Elkind-Hirsch K. et al Aerobic exercise training improves atrial natriuretic peptide and catecholamine-mediated lipolysis in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 2009; 94: 2579-2586
    CrossrefPubMedGoogle Scholar
  • 17 Morley LC, Tang T, Yasmin E. et al Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database of Syst Rev 2017; 11: CD003053 DOI: 10.1002/14651858.CD003053.pub6.
    CrossrefPubMedGoogle Scholar
  • 18 Tan S, Hahn S, Benson S. et al Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance. Eur J Endocrinol 2007; 157: 669-676
    CrossrefPubMedGoogle Scholar
  • 19 Moll E, van Wely M, Lambalk CB. et al Health-related quality of life in women with newly diagnosed polycystic ovary syndrome randomized between clomifene citrate plus metformin or clomifene citrate plus placebo. Hum Reprod 2012; 27: 3273-3278
    CrossrefPubMedGoogle Scholar
  • 20 Huang XM, Wang P, Tal R. et al A systematic review and meta-analysis of metformin among patients with polycystic ovary syndrome undergoing assisted reproductive technology procedures. Int J Gynecol Obstet 2015; 131: 111-116
    CrossrefPubMedGoogle Scholar
  • 21 Zeng XL, Zhang YF, Tian Q. Effects of metformin on pregnancy outcomes in women with polycystic ovary syndrome: A meta-analysis. Medicine 2016 95.
    PubMedGoogle Scholar
  • 22 Kite C, Lahart IM, Afzal I. et al Exercise, or exercise and diet for the management of polycystic ovary syndrome: a systematic review and meta-analysis. Syst Rev 2019; 8: 51
    CrossrefPubMedGoogle Scholar
  • 23 Woodward A, Klonizakis M, Lahart I. et al The effects of exercise on cardiometabolic outcomes in women with polycystic ovary syndrome not taking the oral contraceptive pill: protocol for a systematic review and meta-analysis. Syst Rev 2019; 8: 116
    CrossrefPubMedGoogle Scholar
  • 24 Higgins JPT, Altman DG, Gotzsche PC. et al The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011 343.
    PubMedGoogle Scholar
  • 25 Zhang J, Si QQ, Li JQ. Therapeutic effects of metformin and clomiphene in combination with lifestyle intervention on infertility in women with obese polycystic ovary syndrome. Pakistan J Med Sci 2017; 33: 8-12
    PubMedGoogle Scholar
  • 26 Ma LK, Jin LN, Yu Q. et al [Effect of lifestyle adjustment, metformin and rosiglitazone in polycystic ovary syndrome]. Zhonghua Fu Chan Ke Za Zhi 2007; 42: 294-297
    PubMedGoogle Scholar
  • 27 Otta CF, Wior M, Iraci GS. et al Clinical, metabolic, and endocrine parameters in response to metformin and lifestyle intervention in women with polycystic ovary syndrome: A randomized, double-blind, and placebo control trial. Gynecol Endocrinol 2010; 26: 173-178
    CrossrefPubMedGoogle Scholar
  • 28 Hoeger KM, Kochman L, Wixom N. et al A randomized, 48-week, placebocontrolled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertil Steril 2004; 82: 421-429
    CrossrefPubMedGoogle Scholar
  • 29 Tang T, Glanville J, Hayden CJ. et al Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study. Hum Reprod 2006; 21: 80-89
    CrossrefPubMedGoogle Scholar
  • 30 Ladson G, Dodson WC, Sweet SD. et al The effects of metformin with lifestyle therapy in polycystic ovary syndrome: a randomized double-blind study. Fertil Steril 2011; 95: U1059-U1264
    CrossrefPubMedGoogle Scholar
  • 31 Ladson G, Dodson WC, Sweet SD. et al Effects of metformin in adolescents with polycystic ovary syndrome undertaking lifestyle therapy: a pilot randomized double-blind study. Fertil Steril 2011; 95: U2595-U2645
    CrossrefPubMedGoogle Scholar
  • 32 Tiwari N, Pasrija S, Jain S. Randomised controlled trial to study the efficacy of exercise with and without metformin on women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2019; 234: 149-154
    CrossrefPubMedGoogle Scholar
  • 33 Stener-Victorin E, Zhang H, Li R. et al Acupuncture or metformin to improve insulin resistance in women with polycystic ovary syndrome: study protocol of a combined multinational cross sectional case-control study and a randomised controlled trial. BMJ Open 2019; 9: e024733
    CrossrefPubMedGoogle Scholar
  • 34 AlHussain F, AlRuthia Y, Al-Mandeel H. et al Metformin Improves the Depression Symptoms of Women with Polycystic Ovary Syndrome in a Lifestyle Modification Program. Patient Pref Adherence 2020; 14: 737-746
    CrossrefPubMedGoogle Scholar
  • 35 Naderpoor N, Shorakae S, de Courten B. et al Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis. Hum Reprod Update 2015; 21: 560-574
    CrossrefPubMedGoogle Scholar
  • 36 Kim CH, Chon SJ, Lee SH. Effects of lifestyle modification in polycystic ovary syndrome compared to metformin only or metformin addition: A systematic review and meta-analysis. Sci Rep 2020 10.
    PubMedGoogle Scholar
  • 37 Palomba S, Giallauria F, Falbo A. et al Structured exercise training programme versus hypocaloric hyperproteic diet in obese polycystic ovary syndrome patients with anovulatory infertility: a 24-week pilot study. Hum Reprod 2008; 23: 642-650
    CrossrefPubMedGoogle Scholar
  • 38 Hakimi O, Cameron LC. Effect of Exercise on Ovulation: A Systematic Review. Sports Med 2017; 47: 1555-1567
    CrossrefPubMedGoogle Scholar
  • 39 Harrison CL, Lombard CB, Moran LJ. et al Exercise therapy in polycystic ovary syndrome: a systematic review. Hum Reprod Update 2011; 17: 171-183
    CrossrefPubMedGoogle Scholar
  • 40 Tang T, Lord JM, Norman RJ. et al Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database of Syst Rev 2012; CD003053 DOI: 10.1002/14651858.CD003053.pub5.
    CrossrefPubMedGoogle Scholar
  • 41 Legro RS, Arslanian SA, Ehrmann DA. et al Diagnosis and treatment of polycystic ovary syndrome: an endocrine society clinical practice guideline. J Cli Endocrinol Metab 2013; 98: 4565-4592
    CrossrefPubMedGoogle Scholar
  • 42 Costello MF, Eden JA. A systematic review of the reproductive system effects of metformin in patients with polycystic ovary syndrome. Fertil Steril 2003; 79: 1-13
    CrossrefPubMedGoogle Scholar
  • 43 Lord JM, Flight IH, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 2003; 327: 951-953
    CrossrefPubMedGoogle Scholar
  • 44 Patel R, Shah G. Effect of metformin on clinical, metabolic and endocrine outcomes in women with polycystic ovary syndrome: a meta-analysis of randomized controlled trials. Curr Med Res Opin 2017; 33: 1545-1557
    CrossrefPubMedGoogle Scholar
  • 45 Praharaj SK, Jana AK, Goyal N. et al Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis. Br J Clin Pharmacol 2011; 71: 377-382
    CrossrefPubMedGoogle Scholar
  • 46 Pasquali R, Gambineri A, Biscotti D. et al Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab 2000; 85: 2767-2774
    CrossrefPubMedGoogle Scholar
  • 47 Kolodziejczyk B, Duleba AJ, Spaczynski RZ. et al Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome. Fertil Steril 2000; 73: 1149-1154
    CrossrefPubMedGoogle Scholar
  • 48 Moghetti P, Castello R, Negri C. et al Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: A randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 2000; 85: 139-146
    PubMedGoogle Scholar
  • 49 Chou KH, von Eye Corleta H, Capp E. et al Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: a randomized, double-blind and placebo-controlled trial. Horm Metab Res 2003; 35: 86-91
    Article in Thieme ConnectPubMedGoogle Scholar
  • 50 Diamanti-Kandarakis E, Christakou CD, Kandaraki E. et al Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome. Eur J Endocrinol 2010; 162: 193-212
    CrossrefPubMedGoogle Scholar
  • 51 Liao L, Tian YJ, Zhao JJ. et al Metformin versus metformin plus rosiglitazone in women with polycystic ovary syndrome. Chin Med J 2011; 124: 714-718
    PubMedGoogle Scholar
  • 52 Hirsch A, Hahn D, Kempna P. et al Metformin inhibits human androgen production by regulating steroidogenic enzymes HSD3B2 and CYP17A1 and complex I activity of the respiratory chain. Endocrinology 2012; 153: 4354-4366
    CrossrefPubMedGoogle Scholar
  • 53 Kurzthaler D, Hadziomerovic-Pekic D, Wildt L. et al Metformin induces a prompt decrease in LH-stimulated testosterone response in women with PCOS independent of its insulin-sensitizing effects Reprod Biol Endocrinol. 2014 12.
    PubMedGoogle Scholar
  • 54 Meyer C, McGrath BP, Teede HJ. Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. Diabetes Care 2007; 30: 471-478
    CrossrefPubMedGoogle Scholar
  • 55 Kite CS, Lahart IM, Afzal I. et al Exercise interventions significantly reduce fasting insulin, but not fasting glucose, in women with polycystic ovary syndrome when compared with no intervention: A systematic review and meta-analysis. Diabetic Med 2018; 35: 60
    PubMedGoogle Scholar
  • 56 Patten RK, Boyle RA, Moholdt T. et al Exercise Interventions in Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis Front Physiol. 2020 11.
    PubMedGoogle Scholar
  • 57 Hahn S, Benson S, Elsenbruch S. et al Metformin treatment of polycystic ovary syndrome improves health-related quality-of-life, emotional distress and sexuality. Hum Reprod 2006; 21: 1925-1934
    CrossrefPubMedGoogle Scholar
  • 58 Huang T, Chen PC, Wu MH. et al Metformin improved health-related quality of life in ethnic Chinese women with polycystic ovary syndrome. Health Qual Life Outcomes. 2016 14.
    PubMedGoogle Scholar
  • 59 Tu HP, Lin CH, Hsieh HM. et al Prevalence of anxiety disorder in patients with type 2 diabetes: a nationwide population-based study in Taiwan 2000-2010. Psychiatr Quart 2017; 88: 75-91
    CrossrefPubMedGoogle Scholar
  • 60 Liao LM, Nesic J, Chadwick PM. et al Exercise and body image distress in overweight and obese women with polycystic ovary syndrome: A pilot investigation. Gynecol Endocrinol 2008; 24: 555-561
    CrossrefPubMedGoogle Scholar
  • 61 Thomson RL, Buckley JD, Lim SS. et al Lifestyle management improves quality of life and depression in overweight and obese women with polycystic ovary syndrome. Fertil Steril 2010; 94: 1812-1816
    CrossrefPubMedGoogle Scholar